Inhibitor Therapeutics, Inc. (INTI) stock
Close on Oct 19, 2026Market cap $19.06MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $19.06M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$3.31M
- EPS, diluted
- -$0.01
- Book value per share
- -$0.01
- Diluted shares
- 173M
Trading
- Previous close
- $0.11
- Open
- $0.11
- Day's range
- $0.11 – $0.11
- Volume
- 0
- Average volume (20 days)
- 6,526
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | INTI | S&P 500 | Difference | INTI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.6% | +0.6% | +23.0 pts | ||
| 3 months | +41.8% | +3.4% | +38.5 pts | ||
| Year to date | +144.4% | +13.3% | +131.2 pts | ||
| 1 year | +129.2% | +16.6% | +112.6 pts | ||
| 3 years | +103.7% | +86.4% | +17.3 pts | +26.8% | +23.1% |
| 5 years | -31.3% | +81.9% | −113.1 pts | -7.2% | +12.7% |
| 10 years | -79.6% | +318.9% | −398.5 pts | -14.7% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Inhibitor Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About Inhibitor Therapeutics
Pharmaceutical Preparations
Inhibitor Therapeutics, Inc. is a pharmaceutical development company that focuses on repurposing approved active pharmaceutical ingredients to treat rare diseases, primarily targeting basal cell carcinoma nevus syndrome (Gorlin Syndrome). The company's lead development program centers on an oral formulation of itraconazole, an antifungal agent with anti-angiogenic properties that inhibit vascular growth supporting tumor proliferation. Its primary development candidate is a proprietary micronized and amorphous formulation developed to improve drug bioavailability and absorption for chronic disease management. The company currently operates without commercialized products, directing its activities toward preclinical and clinical evaluation to serve patients managed by dermatologists and Mohs micrographic surgeons.
Company profile, executives and historyInhibitor Therapeutics stock: common questions
What is Inhibitor Therapeutics's stock price?
INTI closed at $0.11 on Oct 19, 2026, up 0.09% on the day.
What is Inhibitor Therapeutics's market cap?
Inhibitor Therapeutics was worth $19.06M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is INTI's P/E ratio?
Inhibitor Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.01), so it has no meaningful P/E ratio.
Does Inhibitor Therapeutics pay a dividend?
No. Inhibitor Therapeutics has not paid a cash dividend over the last twelve months.
How has INTI stock performed over the past year?
Including dividends, INTI returned +129.2% over the past year, against +16.6% for the S&P 500.
Who are Inhibitor Therapeutics's competitors?
Companies most similar to Inhibitor Therapeutics by business, industry and size include QNRX, VRCA, HIND, AZTR, PVLA.
See a number that looks wrong?